Anti-IgE for the Treatment of Chronic Urticaria
Bettina Wedi, Stephan Traidl Department of Dermatology and Allergy, Comprehensive Allergy Center, Hannover Medical School, Hannover, GermanyCorrespondence: Bettina Wedi Email wedi.bettina@mh-hannover.deAbstract: Urticaria and angioedema are very common. Management of chronic urticaria subtypes, whic...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-02-01
|
| Series: | ImmunoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/anti-ige-for-the-treatment-of-chronic-urticaria-peer-reviewed-article-ITT |
| _version_ | 1818949821630775296 |
|---|---|
| author | Wedi B Traidl S |
| author_facet | Wedi B Traidl S |
| author_sort | Wedi B |
| collection | DOAJ |
| description | Bettina Wedi, Stephan Traidl Department of Dermatology and Allergy, Comprehensive Allergy Center, Hannover Medical School, Hannover, GermanyCorrespondence: Bettina Wedi Email wedi.bettina@mh-hannover.deAbstract: Urticaria and angioedema are very common. Management of chronic urticaria subtypes, which usually persist for many years, is challenging. Recent years have demonstrated that targeting IgE with antibodies provides a safe and efficient treatment approach. Whilst several anti-IgE antibodies have been developed, omalizumab is currently the only one approved for use. International and national guidelines recommend its use after failure of antihistamines at standard and increased dose. Whilst not yet approved, many new anti-IgE approaches are currently being investigated in pre-clinical studies or clinical trials. This non-systematic focused review summarizes current knowledge of omalizumab and other anti-IgE biologics in chronic urticaria using data extracted from PubMed, Google Scholar and clinical trial databases, clinicaltrials.gov and clinicaltrials.eu. For adults, there is good evidence from randomized clinical trials and real-world data that symptomatic treatment with omalizumab is efficacious and safe in chronic spontaneous urticaria (CSU), whereas evidence in chronic inducible urticaria (CINDU) and special populations is limited. Easy-to-use tools to identify non-responders and predict the required duration of treatment have not been established yet. Phase 2 b results of ligelizumab have not only demonstrated efficacy and safety but also superiority to omalizumab. Indeed, there is preliminary evidence that omalizumab non- or partial responders benefit from ligelizumab. Whereas further development of quilizumab was discontinued, other approaches, eg UB-221 or DARPins are under investigation. Anti-IgE treatment with omalizumab represents a landmark in the treatment of chronic urticaria, with and without angioedema, and there is light on the horizon suggesting success may come with various next-generation anti-IgE approaches.Keywords: anti-IgE therapy, ligelizumab, monoclonal antibody, omalizumab, quilizumab, UB-221, urticaria |
| first_indexed | 2024-12-20T09:08:47Z |
| format | Article |
| id | doaj.art-de521b463d6c44fbbb4141026dca04ac |
| institution | Directory Open Access Journal |
| issn | 2253-1556 |
| language | English |
| last_indexed | 2024-12-20T09:08:47Z |
| publishDate | 2021-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ImmunoTargets and Therapy |
| spelling | doaj.art-de521b463d6c44fbbb4141026dca04ac2022-12-21T19:45:38ZengDove Medical PressImmunoTargets and Therapy2253-15562021-02-01Volume 10274562248Anti-IgE for the Treatment of Chronic UrticariaWedi BTraidl SBettina Wedi, Stephan Traidl Department of Dermatology and Allergy, Comprehensive Allergy Center, Hannover Medical School, Hannover, GermanyCorrespondence: Bettina Wedi Email wedi.bettina@mh-hannover.deAbstract: Urticaria and angioedema are very common. Management of chronic urticaria subtypes, which usually persist for many years, is challenging. Recent years have demonstrated that targeting IgE with antibodies provides a safe and efficient treatment approach. Whilst several anti-IgE antibodies have been developed, omalizumab is currently the only one approved for use. International and national guidelines recommend its use after failure of antihistamines at standard and increased dose. Whilst not yet approved, many new anti-IgE approaches are currently being investigated in pre-clinical studies or clinical trials. This non-systematic focused review summarizes current knowledge of omalizumab and other anti-IgE biologics in chronic urticaria using data extracted from PubMed, Google Scholar and clinical trial databases, clinicaltrials.gov and clinicaltrials.eu. For adults, there is good evidence from randomized clinical trials and real-world data that symptomatic treatment with omalizumab is efficacious and safe in chronic spontaneous urticaria (CSU), whereas evidence in chronic inducible urticaria (CINDU) and special populations is limited. Easy-to-use tools to identify non-responders and predict the required duration of treatment have not been established yet. Phase 2 b results of ligelizumab have not only demonstrated efficacy and safety but also superiority to omalizumab. Indeed, there is preliminary evidence that omalizumab non- or partial responders benefit from ligelizumab. Whereas further development of quilizumab was discontinued, other approaches, eg UB-221 or DARPins are under investigation. Anti-IgE treatment with omalizumab represents a landmark in the treatment of chronic urticaria, with and without angioedema, and there is light on the horizon suggesting success may come with various next-generation anti-IgE approaches.Keywords: anti-IgE therapy, ligelizumab, monoclonal antibody, omalizumab, quilizumab, UB-221, urticariahttps://www.dovepress.com/anti-ige-for-the-treatment-of-chronic-urticaria-peer-reviewed-article-ITTanti-ige therapyligelizumabmonoclonal antibodyomalizumabquilizumabub-221urticaria |
| spellingShingle | Wedi B Traidl S Anti-IgE for the Treatment of Chronic Urticaria ImmunoTargets and Therapy anti-ige therapy ligelizumab monoclonal antibody omalizumab quilizumab ub-221 urticaria |
| title | Anti-IgE for the Treatment of Chronic Urticaria |
| title_full | Anti-IgE for the Treatment of Chronic Urticaria |
| title_fullStr | Anti-IgE for the Treatment of Chronic Urticaria |
| title_full_unstemmed | Anti-IgE for the Treatment of Chronic Urticaria |
| title_short | Anti-IgE for the Treatment of Chronic Urticaria |
| title_sort | anti ige for the treatment of chronic urticaria |
| topic | anti-ige therapy ligelizumab monoclonal antibody omalizumab quilizumab ub-221 urticaria |
| url | https://www.dovepress.com/anti-ige-for-the-treatment-of-chronic-urticaria-peer-reviewed-article-ITT |
| work_keys_str_mv | AT wedib antiigeforthetreatmentofchronicurticaria AT traidls antiigeforthetreatmentofchronicurticaria |